Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease

NCT00306215 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00306215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00306215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
June 30, 2009
Enrollment
436 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease